Title:
ANTIBODIES DIRECTED AGAINST IL-17
Document Type and Number:
WIPO Patent Application WO/2012/018767
Kind Code:
A3
Abstract:
The disclosure relates to an isolated IL-17-binding agent which comprises an immunoglobulin heavy chain polypeptide comprising SEQ ID NO: 1 and optionally an immunoglobulin light chain polypeptide comprising SEQ ID NO: 23, except that one or more specific of residues of SEQ ID NO: 1 and SEQ ID NO: 23 are replaced with a different residue. The disclosure also provides vectors, compositions, and methods of using the IL-17-binding agent to treat an IL-17-mediated disease.
Inventors:
HORLICK ROBERT (US)
KING DAVID (US)
BOWERS PETER (US)
DALTON JENNIFER (US)
WU BETTY (US)
ROBERTS TRACI (US)
ZHANG XUE (US)
ALTOBELL III LAURENCE (US)
KING DAVID (US)
BOWERS PETER (US)
DALTON JENNIFER (US)
WU BETTY (US)
ROBERTS TRACI (US)
ZHANG XUE (US)
ALTOBELL III LAURENCE (US)
Application Number:
PCT/US2011/046201
Publication Date:
May 10, 2012
Filing Date:
August 02, 2011
Export Citation:
Assignee:
ANAPTYSBIO INC (US)
HORLICK ROBERT (US)
KING DAVID (US)
BOWERS PETER (US)
DALTON JENNIFER (US)
WU BETTY (US)
ROBERTS TRACI (US)
ZHANG XUE (US)
ALTOBELL III LAURENCE (US)
HORLICK ROBERT (US)
KING DAVID (US)
BOWERS PETER (US)
DALTON JENNIFER (US)
WU BETTY (US)
ROBERTS TRACI (US)
ZHANG XUE (US)
ALTOBELL III LAURENCE (US)
International Classes:
C07K16/00; A61K39/395; C12N5/16; C12N15/00; C12P21/06
Foreign References:
| US20090280131A1 | 2009-11-12 | |||
| US20090175881A1 | 2009-07-09 | |||
| US20100080812A1 | 2010-04-01 | |||
| US20100086538A1 | 2010-04-08 | |||
| US20070031414A1 | 2007-02-08 |
Other References:
GENOVESE ET AL.: "LY2439821, a Humanized Anti-Interleukin-17 Monoclonal Antibody, in the Treatment of Patients With Rheumatoid Arthritis.", ARTHRITIS RHEUM., vol. 62, no. 4, April 2010 (2010-04-01), pages 929 - 39, XP002669154
See also references of EP 2601217A4
See also references of EP 2601217A4
Attorney, Agent or Firm:
KOLOM, Melissa et al. (Suite 4900Chicago, Illinois, US)
Download PDF: